Joseph A. Ware
机构:Medical Diagnostic Laboratories (United States), University of Washington Bothell
发表论文 129 篇 · 总被引 6938 次 · h-index 29
代表论文
- Abstract 5668: Using clinical utility index (CUI) to determine the optimal biological dose of a nonfucosylated anti-TIGIT antibody: A proposed alternative to maximum tolerated dose (MTD) (2023 · Cancer Research · 被引 2)
- Abstract 5060: Tucatinib does not alter oxaliplatin PK or associated renal function: An OCT2 and MATE transport inhibition study (2023 · Cancer Research)
- Supplementary Tables 1 through 4 and Supplementary Figures 1 through 7 from Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors (2023)
- Data from Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors (2023)
- Supplementary Tables 1 through 4 and Supplementary Figures 1 through 7 from Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors (2023)
- Data from Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors (2023)